New Delhi: Dr Reddy's Laboratories on Friday said it has entered into a definitive agreement with Upsher-Smith Laboratories to sell the US and select territory rights of its neurology branded products -- Tosymra and Zembrace -- for over USD 110 million (approx Rs 765 crore).
"Under the agreement, Dr Reddy's will receive USD 70 million as upfront consideration, USD 40.5 million in near-term milestones and additional financial considerations including, existing contractual obligation and inventory," the company said in a regulatory filing.